U.S. Markets close in 5 hrs 23 mins

Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA

Stock Monitor: Seattle Genetics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar") all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLRB as the Company's latest news hit the wire. On May 02, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) to its lead phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Seattle Genetics, Inc. (NASDAQ: SGEN), which also belongs to the Healthcare sector as the Company Cellectar Biosciences. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SGEN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Cellectar Biosciences most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CLRB

About CLR 131

CLR 131 is Cellectar's investigational radio-iodinated PDC therapy that exploits the tumor-targeting properties of the Company's proprietary phospholipid ether (PLE) and PLE analogs. CLR 131 selectively delivered radiation to malignant tumor cells, thus minimizing radiation exposure to normal tissues. The therapy is currently in a Phase-2 clinical study in relapsed or refractory (R/R) MM and a range of B-cell malignancies, and also in a Phase-1 clinical study in patients with (R/R) MM exploring fractionated dosing.

For Q2 2018, Cellectar is planning to initiate a Phase-1 study with CLR 131 in pediatric solid tumors and lymphoma, as well as a Phase-1 study in combination with external beam radiation for head and neck cancer.

About Neuroblastoma

Neuroblastoma, which is a neoplasm of the sympathetic nervous system, is one of the most common extracranial solid tumor of childhood, accounting for approximately 7.8% of childhood cancers in the United States. Neuroblastoma is also recognized by the FDA as an orphan disease. The incidence is about 10.54 cases per 1 million per year in children younger than 15 years, and 90% of children are younger than 5 years at diagnosis. Approximately 50% of patients present with metastatic disease require systemic treatment. Although the prognosis is favorable in children under one year of age with an 86% to 95% 5-year survival, in children aged 1 to 14 years, the 5-year survival ranges from 34% to 68%.

Benefits of the Rare Pediatric Disease Designation (RPDD) to Cellectar

The FDA grants the RPDD for diseases that primarily affect children from birth to 18 years of age, and affect fewer than 200,000 persons in the US. This program is intended to encourage the development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.

If CLR 131 is approved by the FDA for neuroblastoma, the RPDD may enable Cellectar to receive a priority review voucher. Priority review vouchers can be used by the sponsor to receive Priority Review for a future NDA or BLA submission, which would reduce the FDA review time from twelve months to six months. Currently, these vouchers can also be transferred or sold to another entity. Over the last 16 months, 5 priority review vouchers were sold for between $110 million to $150 million each.

About Cellectar Biosciences, Inc.

Cellectar is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The Company plans to develop proprietary drugs independently and through research and development (R&D) collaborations. The core drug development strategy is to leverage its PDC platform to develop therapeutics that specifically target treatment to cancer cells. Through R&D collaborations, Cellectar's strategy is to generate near-term capital, supplement internal resources, gain access to novel molecules or payloads, accelerate product candidate development, and broaden its proprietary and partnered product pipelines.

Stock Performance Snapshot

May 3, 2018 - At Thursday's closing bell, Cellectar Biosciences' stock fell 1.74%, ending the trading session at $1.13.

Volume traded for the day: 102.22 thousand shares.

Stock performance in the last month – up 0.64%

After yesterday's close, Cellectar Biosciences' market cap was at $18.96 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors